Safety and Efficacy of Herbal Tea in Type 2 Diabetics (DIABHerbMix)
Safety and Efficacy of a Complex Herbal Tea Mixture in Type 2 Diabetics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Osijek, Croatia, 31000
- Department of Food and Nutrition Research, Faculty of Food Technology
-
Osijek, Croatia, 31000
- Health Centre Osijek
-
Osijek, Croatia, 31000
- University Hospital Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- signed informed consent
- Croatian-speaking
- stable therapy for at least 3 months prior enrollment
- not taking any dietary supplements, especially herbal-based
- not taking any other herbal medicine (as a tea or a supplement)
- stable dietary and lifestyle patterns for at least 3 months prior enrollment
Exclusion Criteria:
- type 1 diabetes
- severe somatic disorder (oncological disease, hepatic, renal or autoimmune disease)
- pregnancy
- inability to fill in questionnaires in Croatian
- cognitive impairment
- psychiatric disorder
- undergoing current treatment for a major medical illness such as malignancy, autoimmune or immune deficiency disorder
- clotting disorders
- having nutritional deficiency (e.g. iron deficiency)
- current or history of eating disorder (anorexia, bulimia or EDNOS)
- current use of weight loss interventions (drugs; exercise interventions)
- regular use of dietary supplements, especially herbal-based
- regular use of herbal medicine (as a tea or a supplement)
- significant changes in diet or lifestyle patterns (e.g. increased physical activity) in the last 3 months prior the enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SCREENING
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Intervention
Herbal Tea Mixture is consisted of: Vaccinium myrtillus L. folium, Morus nigra L. folium, Phaseolus vulgaris L. pericarpium, Viscum album L. herba, Urtica dioica L. radix, Gentiana lutea L. radix, Taraxacum officinale W. radix, Cichorium intybus L. herba, Teucrium chamaedrys L. herba, Stevia rebaudiana folium.
|
Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks.
The first tea needs to be taken in the morning prior any meal.
The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Other Names:
|
|
ACTIVE_COMPARATOR: Control
Herbal Tea Mixture without antidiabetic properties is consisted of: Achillea millefolium L. herba, Teucrium montanum L. herba, Glechoma hederacea L. herba, Eupatorium cannabinum L. herba, Humulus lupulus L. lupulin, Artemisia absinthium L. herba, Salvia officinalis L.
|
Patients will be instructed to take 250 mL of freshly prepared tea (1 tea spoon or 3 g of tea, pour over 250 mL of boiling water and leave aside for 15 min) 2 times per day during 12 weeks.
The first tea needs to be taken in the morning prior any meal.
The second can be taken at any time during the day but with at least 4 hour difference from the first cup.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of patients with adverse event
Time Frame: Starting from baseline, once per week until study completion at week 12.
|
Adverse event (e.g.
hypoglycaemia) reporting through direct contact researcher-patient.
|
Starting from baseline, once per week until study completion at week 12.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycated Hemoglobin
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood HbA1c (%)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Fasting Glucose
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood Glucose (mmol/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Creatinine
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of Creatinine (µmol)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Urea
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of Urea (mmol/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Total Proteins
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of Total Proteins (g/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Alanine transaminase
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of liver enzymes Alanine transaminase (ALT in U/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Aspartate transaminase
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of liver enzymes Aspartate transaminase (AST in U/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Alkaline phosphatase
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of liver enzymes Alkaline phosphatase (ALP in U/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Gamma-glutamyl transpeptidase
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Blood concentration of liver enzymes Gamma-glutamyl transpeptidase (GGT in U/L)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Body Weight
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Change in body weigh (in kg), Body Mass Index in kg/m2, waist circumference in cm
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Body Mass Index
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Change in Body Mass Index (kg per square meter)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
|
Waist Circumference
Time Frame: At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Change in waist circumference (in cm)
|
At enrollment (baseline) and at the end of the intervention (at 12 weeks).
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- JJStrossmayerU-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.